The model also revealed how molecular subgroups could behave very differently if a patient's cancer returns. You may need antibiotics. Charitable organisation. Ay effects will also depend on other chemotherapy drugs you are having at the same time or have received in the past, and your age. Docetaxel is the generic non-branded name of the drug, but you may hear it called by one of its brand names such as Taxotere.
They used this information to create a statistical tool that can better predict if, and when a women's breast cancer could come back. See more in-depth in situ breast carcinoma diagnosis and treatment statistics. Breast cancer is more common in White females than in Asian or Black females. Find out more about your body and your breasts after treatment. Like any treatment, docetaxel chemotherapy can cause side effects. If the number of blood cells is too low, your next course of treatment may be delayed or the dose of the chemotherapy reduced. Breast cancer statistics.
In males in the UK, breast cancer is not among the 20 most common cancers, with around new cases in It also provides information about cancer and runs campaigns aimed at raising awareness of the disease and influencing public policy. If this is the case speak to your specialist team — they may be able to suggest ways of managing this. If changes to your heart rate and blood pressure happen, they can usually be treated easily and you will not have to stop your treatment. Targeted breast cancer treatment approved for NHS use in England.
Professor Karen Vousden, Cancer Research UK's chief scientist, said: "This study provides some valuable new insights into how we might identify women whose breast cancer is likely to return. News Sign up for news alerts Submit your news. This is because being overweight causes more oestrogen to be produced by your body, which can increase your risk of some types of breast cancer. How is docetaxel given? An immunotherapy treatment for triple negative breast cancer has been provisionally rejected for NHS use in England.